Shield Therapeutics, the mineral medicines company, has two new appointments with Dr Lynn Drummond (pictured) joining the board as a non-executive director, and Dr Julian Howell joining the senior management team as group medical director and VP of drug development.

Dr Drummond has a track record within the life sciences sector, bringing over 25 years of management and advisory experience. She spent 16 years at Rothschild in London, most recently as a managing director within the investment banking division, with a particular focus on transactions within the healthcare sector.

Prior to this she worked in the Cabinet Office of the UK Government as private secretary to the chief scientific advisor and spent the early part of her career as a research scientist.

Dr Howell is a pharmaceutical physician with more than 14 years of medical affairs and pharmaceutical development experience across a broad range of therapeutic areas.

He joins Shield following six years at ProStrakan where he led the clinical development and drug safety group, achieving six product approvals in the US and Europe.